An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues

Myopia Clinical Trial

— ID11-56  

Official title:

EVALUATION OF THE EFFECTS OF CLEAR CARE® / AOSEPT® PLUS HYDROGEN PEROXIDE SOLUTION ON THE EYELID TISSUES - Part III: COMPARATIVE EVALUATION WITH RENU® MPS OVER 3 MONTH OF WEAR - CONTROL EVALUATION WITH AIR OPTIX® AQUA and ACUVUE® 2®

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01594294
• Other study ID #: M-11-09
• Status: Completed
• Phase: N/A
• First received: May 7, 2012
• Last updated: June 27, 2014
• Start date: April 2012
• Est. completion date: June 2013

Study information

• Verified date: June 2014
• Source: Alcon Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to assess and compare the effect of the repeated usage of 2 different care systems (one hydrogen peroxide based cleaning and disinfecting system and one PHMB containing multipurpose system) with ACUVUE® 2® and AIR OPTIX® AQUA contact lenses worn on a daily wear basis for a 3-month period.

Description:

This study was divided into 2 periods, a Screening Phase and an Investigational Phase. During the Screening Phase, subjects were fitted and dispensed with either ACUVUE® 2® (for current hydrogel wearers) or AIR OPTIX® AQUA (for current silicone hydrogel wearers) contact lenses and used COMPLETE® MPS Easy Rub® Formula to clean and disinfect their lenses. At the completion of the Screening Phase, the symptomatic status of the subjects was re-assessed. Those subjects who qualified proceeded to the Investigational Phase and were dispensed with new pair of study contact lenses identical to the lenses they wore during the Screening Phase to use in conjunction with the allocated study care product, CLEAR CARE® /AOSEPT® Plus or ReNu MultiPlus®.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Read and understand the Participant Information Sheet;

• Read, sign, and date an Informed Consent;

• Successfully wearing a frequent replacement hydrogel or silicone hydrogel contact lens brand under a frequent replacement (biweekly or monthly) daily wear modality;

• Classified as symptomatic according to protocol-specified criteria;

• Agree to wear study contact lenses as directed for the duration of the study;

• Best corrected visual acuity (BCVA) of 6/9 or better in each eye;

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Any known sensitivity or intolerance to any of the contact lenses or contact lens care products to be used;

• Monocular vision (only one eye with functional vision or only one eye fitted with contact lenses);

• History of seasonal allergies, which may have an adverse impact on contact lens wear, or data and information obtained in this study;

• Systemic disease or use of medication which might interfere with contact lens wear or produce dry eye side effects;

• Ocular allergies or ocular disease which might interfere with contact lens wear or data and information obtained in this study;

• Active ocular infection;

• Use of any concomitant topical ocular medications during the study period;

• Significant ocular anomaly;

• Previous ocular surgery;

• History of recent, significant changes in visual acuity;

• Any medical condition that might be prejudicial to the study;

• Pregnant, planning to be become pregnant, or lactating at time of enrollment;

• Any infectious disease (e.g. hepatitis, tuberculosis), immunosuppressive disease (e.g. HIV), or diabetes;

• Participation in an investigational drug or device study within 30 days of entering study;

• Other protocol-defined exclusion criteria may apply.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Myopia

Intervention

Device:
• AOSEPT® Plus contact lens solution
Hydrogen peroxide-based cleaning and disinfection system
• ReNu MultiPlus® contact lens solution
Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
• Etafilcon A contact lenses
Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
• Lotrafilcon B contact lenses
Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
• COMPLETE® MPS Easy Rub® Formula contact lens solution
PHMB 0.0001% and poloxamer 0.05% multipurpose solution

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alcon Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Papillae	Eyelid papillae (bumps on the inner eyelid) were recorded separately for three zones of the upper lid and overall for the lower lid on a 5-point forced choice scale: 0 = None; 1 = Slight (diffuse papillae); 2 = Mild (diffuse & tufts papillae); 3 = Moderate (moderate & tufts papillae); 4 = Severe (giant papillae). The maximum value represents the worse grade in any zone. Both eyes were included in the model for analysis. Contact lenses were not worn for this assessment.	Baseline (Day 0), Month 3	No
Primary	Maximum Eyelid Hyperaemia	Eyelid hyperaemia (redness) was recorded separately for three zones of the upper lid and overall for the lower lid on a 5-point forced choice scale: 0 = Clear; 1 = Slight redness; 2 = Mild redness; 3 = Moderate redness; 4 = Severe redness). The maximum value represents the worst grade in any zone. Both eyes were included in the model for analysis. Contact lenses were not worn for this assessment.	Baseline (Day 0), Month 3	No
Primary	Mean Upper Eyelid Redness	The contact lenses were removed and upper eyelid redness was objectively measured through digital images. The coverage of the palpebral surface by blood vessels is expressed as percentage of the total surface measured. Both eyes were included in the model for analysis. Contact lenses were not worn for this assessment.	Baseline (Day 0), Month 3	No
Primary	Mean Upper Eyelid Margin Staining	The contact lens was removed and ophthalmic dye was instilled. Upper eyelid margin staining was objectively measured through digital images. The extent of true staining (i.e., the total area of lid margin covered by staining) was recorded. Both eyes were included in the model for analysis. Contact lenses were not worn for this assessment.	Baseline (Day 0), Month 3	No
Secondary	Median Non-Invasive Pre-Lens Tear Film Break Up Time (PL-NIBUT)	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eyelid and the contact lens). The time required for a dry spot to appear on the pre-lens surface after blinking is referred to as the pre-lens tear film break up time. PL-NIBUT was evaluated using a biomicroscope with a diffuse illumination source, i.e., Tearscope. A longer PL-NIBUT indicates a more stable tear film and greater on-eye lens wettability. Three PL-NIBUT measurements were recorded, and the median value was used for analysis. Both eyes were included in the model for analysis. Contact lenses were on-eye for this assessment.	Month 3	No